LincRNA Targeting for B-ALL Detection and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting acute lymphoblastic leukemia (ALL) are often ineffective at early stages and can have severe side effects, with a need for non-toxic and donor-independent therapies that can target specific cytogenetic abnormalities associated with the disease.
Innovation Solution
The use of long intergenic non-coding RNAs (lincRNAs), particularly BALIR-2, as diagnostic and therapeutic targets, where specific nucleic acid molecules and expression vectors are developed to inhibit BALIR-2 expression, thereby modulating apoptosis and treatment response in B-ALL cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy, radiation, or bone marrow transplant is used to treat ALL, then treatment effectiveness is improved, but patient toxicity and donor dependency increase
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (lincRNA expression) that drives ALL pathogenesis, separating the therapeutic action from the non-specific toxic effects of conventional chemotherapy. By focusing on the root molecular cause rather than general cellular damage, the treatment achieves efficacy while reducing harm to healthy tissues.
Solution Approach 2:
The patent introduces lincRNA-targeting molecules as intermediaries that specifically bind to and inhibit the pathogenic lincRNA. This intermediary approach allows for precise molecular intervention that avoids the direct cellular toxicity of conventional chemotherapeutic agents while still achieving cancer cell elimination.
2Reliability
If conventional detection methods are used for ALL, then diagnosis is achieved, but early stage detection capability is insufficient
Solution Approach 1:
The patent employs lincRNA expression analysis as a preliminary detection method that can identify ALL at very early stages, before the disease progresses to more advanced states. This early molecular detection allows for intervention at the most treatable stage, reducing the time loss between disease onset and diagnosis.
Solution Approach 2:
The patent replaces conventional mechanical or morphological detection methods with molecular biology-based detection of lincRNA expression. This substitution enables detection at the molecular level, providing earlier and more sensitive diagnosis compared to traditional methods that rely on observable cellular or tissue changes.
3Object-affected harmful factors
If lincRNA-targeting therapy is used to reduce toxicity, then patient safety is improved, but treatment mechanism complexity increases
Solution Approach 1:
The patent extracts the specific lincRNA sequence information and develops targeted molecules based on this extracted genetic signature. This extraction approach simplifies the therapeutic strategy by focusing on a single molecular target rather than requiring complex multi-component systems, making the treatment mechanism more manageable despite the molecular precision required.
Data Source
AI summary
The instant disclosure relates to the finding that lincRNA expression is associated with particular cytogenetic abnormalities and is related to disease pathogenesis of certain cancers. Long intergenic non-coding RNAs (lincRNAs) have been found to play a role in gene regulation, but their expression has not been described in B acute lymphoblastic leukemia (B-ALL). Methods and compositions are provided regarding B-ALL associated long intergenic RNAs (BALIRs).